Sat, October 5, 2024
AUS Edition NZ Edition UK Edition CA Edition USA Edition FRA Edition GER Edition ESP Edition ITA Edition NLD Edition
PRT Edition SWE Edition GRC Edition IND Edition POL Edition BRA Edition ZAF Edition RUS Edition CHN Edition UAE Edition
Kalkine Media ASX Share Market News & Research
Kalkine Media ASX Share Market News & Research
  1. Home
  2. Companies
  3. CSLLY
Healthcare
Facebook Twitter Linkedin

CSL Ltd (OTC:CSLLY)

99.16 USD

+0.090 0.091%
Last Updated at: 2024-10-02T20:00:00Z

CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

45 Poplar Road, Parkville, VIC, Australia, 3052

61 3 9389 1911

https://www.csl.com.au

Employees: 32065

Key Executives

Sr. No. Name Title Year Born
1. Mr. Paul R. Perreault B.A. MD, CEO & Exec. Director 1957
2. Ms. Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI Chief Financial Officer 1965
3. Dr. Paul F. McKenzie Ph.D. Chief Operating Officer 1966
4. Mr. Mark Dehring Head of Investor Relations NA
5. Mr. Gregory Boss B.S., BS(Hons), J.D. Exec. VP of Legal & Group Gen. Counsel 1961
6. Christina Hickie Sr. Mang. of Communications NA
7. Ms. Elizabeth Walker B.A., M.S. Exec. VP & Chief HR Officer 1970
8. Dr. Karen Etchberger Exec. VP of Quality & Bus. Services 1958
9. Dr. Wilfried Freudenberg Department Head of Albumin & Immunoglobulins Production NA
10. Ms. Jemimah Brennan Head of Communications - Asia Pacific NA

Peers

Sector: Healthcare

Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE(x) Forward PE(x) Price Sales TTM(x) Price to Book Value(x) Enterprise Value to Revenue(x) Enterprise Value to EBITDA(x)
NVO

Novo Nordisk A/S

 -0.940 0.807% 116.24 41.580 31.153 2.134 32.989 2.113 4.700
NONOF

Novo Nordisk A/S

 0.000 0.000% 116.2 41.060 31.250 2.078 33.111 2.113 4.700
VRTX

Vertex Pharmaceuticals Inc

 -9.265 2.005% 460 29.670 24.331 10.385 5.832 9.334 20.004
REGN

Regeneron Pharmaceuticals Inc

 -24.030 2.310% 1037.5 29.070 20.121 7.570 3.823 6.950 19.423

Income Statement

(Currency in USD)
Breakdown 30-06-2023 30-06-2022 30-06-2021 30-06-2020 30-06-2019
Income Before Tax 2663M 2779.6M 2963.1M 2572.7M 2341.1M
Minority Interest -50M - - - 0M
Net Income 2194M 2254.7M 2375M 2102.5M 1918.7M
Selling General Administrative 1086M 688M 731.7M 691.8M 574.8M
Gross Profit 6708M 5663.5M 5798.6M 5176.1M 4748.7M
Reconciled Depreciation 831M 542.5M 495.3M 610.956M 536.026M
Ebit 3071M 2922.4M 3198.18M 2723.5M 2517.8M
Ebitda 3902M 3464.9M 3629.2M 3143.3M 2893.2M
Depreciation And Amortization 831M 542.5M 431.02M 419.8M 375.4M
Operating Income 4884.054M 4239.467M 4174.168M 3936.209M 3566.698M
Other Operating Expenses 3989.22M 2951.839M 2322.198M 2037.439M 2049.569M
Interest Expense 408M 142.8M 170.8M 150.8M 176.7M
Tax Provision 419M 524.9M 588.1M 685.123M 602.31M
Interest Income 38M 17.4M 3.9M 10.2M 19.678M
Net Interest Income -406M -160.6M -166.9M -209.529M -232.283M
Income Tax Expense 419M 524.9M 588.1M 470.2M 422.4M
Total Revenue 13174M 10493.1M 10265.3M 9100.5M 8509.9M
Total Operating Expenses 4606M 3347.4M 3208.6M 2929.7M 2648.8M
Cost Of Revenue 6466M 4829.6M 4466.7M 3924.4M 3761.2M
Total Other Income Expense Net 136M 81.6M 44.7M 50.3M 28.7M
Net Income From Continuing Ops 2244M 2254.7M 2375M 3063.529M 2735.919M
Net Income Applicable To Common Shares 2194M 2254.7M 2375M 2102.5M 1918.7M

Balance Sheet

(Currency in USD)
Breakdown 30-06-2023 30-06-2022 30-06-2021 30-06-2020 30-06-2019
Total Assets 36234M 28346M 18156.9M 15464.6M 12314.4M
Intangible Assets 8367M 1450.8M 1481.6M 986M 776.5M
Other Current Assets 9M 4.2M 231.8M 180.8M 138.2M
Total Liab 18408M 13768.5M 9775.6M 8937.2M 7063.1M
Total Stockholder Equity 15786M 14577.5M 8381.3M 6527.4M 5251.3M
Other Current Liab 5687.303M 9437.774M 49.7M 3.2M 2.8M
Common Stock 517M 483.8M 483.8M -4561M -4603M
Capital Stock 517M 483.8M -4504.6M -4561M -4603M
Retained Earnings 14621M 13503.4M 12252.7M 10752.1M 9612.3M
Good Will 8079M 1187.3M 1188.1M 1154.2M 1101.8M
Other Assets 1177M 938.6M 561.5M 572.9M 411.7M
Cash 1548M 10436.4M 1808.8M 1194.4M 657.8M
Cash And Equivalents - - - - -
Total Current Liabilities 4608M 7108.2M 3103.6M 2141.5M 2188.2M
Current Deferred Revenue -2954.303M -7415.374M 2057.1M 1477.7M 1342.2M
Net Debt 10679M -778.6M 3998.1M 4798.4M 4005M
Short Term Debt 1055M 4494M 473.8M 202.3M 420.6M
Short Long Term Debt 964M 4420.5M 396M 180.679M 595.323M
Short Long Term Debt Total 12227M 9657.8M 5806.9M 5992.8M 4662.8M
Other Stockholder Equity -29492M -26783.813M -16340.201M -15580.083M -18294.76M
Property Plant Equipment 9352M 8308.6M 7536M 6305.4M 4484.3M
Total Current Assets 9259M 16460.7M 7389.7M 6446.2M 5540.1M
Long Term Investments 173M 402.9M 21.5M 20.691M 14.117M
Short Term Investments - - 4.8M 3.3M 0.4M
Net Receivables 1905M 1483.2M 1563.7M 1558.2M 1704.9M
Long Term Debt 9564M 3862.5M 4228.5M 8426.927M 6021.246M
Inventory 5466M 4333M 3780.6M 3509.5M 3038.8M
Accounts Payable 820M 591.8M 523M 458.3M 422.6M
Accumulated Other Comprehensive Income 648M 590.3M 633.2M 336.3M 242M
Non Currrent Assets Other 102M 18.2M 10.5M 15.6M 23.1M
Non Current Assets Total 26975M 11885.3M 10767.2M 9018.4M 6774.3M
Capital Lease Obligations 1699M 1374.8M 1182.4M 124.435M 32.226M
Long Term Debt Total - - - - 0M

Cash Flow

(Currency in USD)
Breakdown 30-06-2023 30-06-2022 30-06-2021 30-06-2020 30-06-2019
Investments -11843M -387.7M -387.7M -387.7M -387.7M
Total Cashflows From Investing Activities -11843M -1636.1M -1673.2M -1366.7M -1287.3M
Total Cash From Financing Activities 456M 7675.9M -1401.8M -642.7M -491.5M
Net Income 3294.072M 3266.142M 3167.3M 3046.523M 2732.996M
Change In Cash -8825M 8604.3M 578.8M 493.5M -154.9M
Begin Period Cash Flow 10334M 1730.1M 1151.3M 657.8M 812.7M
End Period Cash Flow 1509M 10334.4M 1730.1M 1151.3M 657.8M
Total Cash From Operating Activities 3905.141M 3807.844M 4830.166M 3605.547M 2342.283M
Depreciation 1088.515M 647.435M 533.84M 508.599M 442.134M
Other Cashflows From Investing Activities - -0.7M -6.1M 18.7M -2.5M
Dividends Paid -1239M -1038.7M -958M -883.1M 806.8M
Change To Inventory -1361.77M -1306.457M -490.365M -993.145M -795.243M
Sale Purchase Of Stock 2539M 4092.7M 38.7M 1652.7M 898.5M
Other Cashflows From Financing Activities -80M -50.1M -68M -55.1M -4.8M
Capital Expenditures 1692M 1247.7M 1667.1M 1367.6M 1284.8M
Change In Working Capital -1319.731M -1371.635M -441.688M -802.022M -1318.14M
Other Non Cash Items -477.445M -105.733M 1129.026M 50.425M -832.847M
Free Cash Flow 2213.141M 2560.144M 3163.066M 2237.947M 1057.483M

No data found

Disclaimer

Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

Related Articles

Code Price Chg %Chg
View All
Code Price Chg %Chg
View All
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
Open in the App